By Fineline Cube Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted its Phase II clinical trial application for the combination of BA1106 (anti-CD25 monoclonal antibody) and BA1104 (nivolumab biosimilar) in driver gene-negative non-small cell lung cancer (NSCLC).
The multicenter, single-arm, open-label study will evaluate the efficacy, safety, and pharmacokinetic (PK) profile of the regimen in patients with advanced NSCLC lacking actionable EGFR, ALK, ROS1, or other driver mutations—a population heavily reliant on immunotherapy but with limited durable response rates to PD-1 monotherapy.
Asset Profiles & Innovation Status
| Molecule | Type | Key Differentiation | Development Stage |
|---|---|---|---|
| BA1106 | First-in-China anti-CD25 innovative mAb for solid tumors | Targets regulatory T cells (Tregs) in tumor microenvironment to overcome immunosuppression | Phase II (NMPA filing accepted) |
| BA1104 | Biosimilar of Opdivo® (nivolumab) | Demonstrates high analytical and functional similarity to originator | Phase I completed; biosimilarity established |
Scientific Rationale & Early Clinical Signals
- Mechanism: BA1106 depletes or modulates CD25+ regulatory T cells (Tregs), which suppress antitumor immunity—potentially enhancing PD-1 blockade by BA1104
- Phase I Results: Combination showed promising efficacy signals across multiple tumor types, including lung adenocarcinoma, lung squamous cell carcinoma, and gastric cancer
- Safety: Favorable tolerability with no unexpected immune-related adverse events (irAEs), suggesting manageable risk profile
Strategic Implications for Boan Biotech
- Innovation Milestone: BA1106 is the first domestically developed anti-CD25 antibody to enter clinical trials for solid tumors in China, marking a shift from biosimilars to novel immuno-oncology
- Commercial Synergy: Pairing an innovative Treg-targeting agent with an in-house nivolumab biosimilar creates a differentiated, vertically integrated combo
- Market Opportunity: Driver-negative NSCLC represents ~40% of Chinese NSCLC cases; current PD-1 monotherapy yields <20% objective response rate
- Global Potential: If successful, the data could support international partnerships or IND filings in regions with high unmet need
Competitive Landscape
While global pharma explores Treg-targeting strategies (e.g., anti-CTLA-4, CCR4 inhibitors), CD25 remains an underexploited target due to historical concerns about systemic T-cell depletion. Boan’s tumor-focused approach may offer a safer therapeutic window.
Forward‑Looking Statements
This brief reflects regulatory acceptance of a clinical trial application. Enrollment, efficacy outcomes, and approval timelines remain subject to trial execution and regulatory review.-Fineline Info & Tech